不利影响
生物
癌症
免疫疗法
癌症免疫疗法
嵌合抗原受体
免疫系统
封锁
食品药品监督管理局
免疫学
生物信息学
药理学
受体
遗传学
生物化学
作者
Michael Dougan,Adrienne Luoma,Stephanie K. Dougan,Kai W. Wucherpfennig
出处
期刊:Cell
[Elsevier]
日期:2021-03-01
卷期号:184 (6): 1575-1588
被引量:107
标识
DOI:10.1016/j.cell.2021.02.011
摘要
During the past decade, immunotherapies have made a major impact on the treatment of diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and Drug Administration (FDA)-approved checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies, but also limit the development and use of combination therapies. Fundamentally, these adverse events highlight the intricate balance of pro- and anti-inflammatory pathways that regulate protective immune responses. Here, we discuss the cellular and molecular mechanisms of inflammatory adverse events, current approaches to treatment, as well as opportunities for the design of immunotherapies that limit such inflammatory toxicities while preserving anti-tumor efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI